Evidence map›Paper›PMID 27807066›Full record

ArticleCancer genomics & proteomics

Differential Expression of Ccn4 and Other Genes Between Metastatic and Non-metastatic EL4 Mouse Lymphoma Cells.

Manpreet S Chahal, H Teresa Ku, Zhihong Zhang, Christian M Legaspi, Angela Luo, Mandi M Hopkins, Kathryn E Meier

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer genomics & proteomics. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Frontiers in pharmacology · 2018
    Article
  3. The role of CCN4/WISP-1 in the cancerous phenotype.Cancer management and research · 2018
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Manpreet S ChahalDepartment of Translational Research and Cellular Therapeutics, College of Pharmacy, Washington State University, Spokane, WA, U.S.A.
H Teresa KuDivision of Development & Translational Diabetes and Endocrine Research, Beckman Research Institute of City of Hope, Duarte, CA, U.S.A.
Zhihong ZhangDepartment of Translational Research and Cellular Therapeutics, College of Pharmacy, Washington State University, Spokane, WA, U.S.A.
Christian M LegaspiDepartment of Translational Research and Cellular Therapeutics, College of Pharmacy, Washington State University, Spokane, WA, U.S.A.
Angela LuoDivision of Development & Translational Diabetes and Endocrine Research, Beckman Research Institute of City of Hope, Duarte, CA, U.S.A.
Mandi M HopkinsDepartment of Translational Research and Cellular Therapeutics, College of Pharmacy, Washington State University, Spokane, WA, U.S.A.
Kathryn E MeierDepartment of Translational Research and Cellular Therapeutics, College of Pharmacy, Washington State University, Spokane, WA, U.S.A. kmeier@wsu.edu.
Washington State University Spokane · USCity of Hope · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPrevious work characterized variants of the EL4 murine lymphoma cell line. Some are non-metastatic, and others metastatic, in syngenic mice. In addition, metastatic EL4 cells were stably transfected with phospholipase D2 (PLD2), which further enhanced metastasis. MATERIALS AND

methodsMicroarray analyses of mRNA expression was performed for non-metastatic, metastatic, and PLD2-expressing metastatic EL4 cells.

resultsMany differences were observed between non-metastatic and metastatic cell lines. One of the most striking new findings was up-regulation of mRNA for the matricellular protein WNT1-inducible signaling pathway protein 1 (CCN4) in metastatic cells; increased protein expression was verified by immunoblotting and immunocytochemistry. Other differentially expressed genes included those for reproductive homeobox 5 (Rhox5; increased in metastatic) and cystatin 7 (Cst7; decreased in metastatic). Differences between PLD2-expressing and parental cell lines were limited but included the signaling proteins Ras guanyl releasing protein 1 (RGS18; increased with PLD2) and suppressor of cytokine signaling 2 (SOCS2; decreased with PLD2).

conclusionThe results provide insights into signaling pathways potentially involved in conferring metastatic ability on lymphoma cells.

Indexed as

Microarray AnalysisAnimalsCCN Intercellular Signaling ProteinsCell Line, TumorCystatinsDisease Models, AnimalGene Expression Regulation, NeoplasticHomeodomain ProteinsHumansLymphomaMiceNeoplasm MetastasisPhospholipase DProto-Oncogene ProteinsRNA, MessengerSignal TransductionCCN4 protein, mouseCCN Intercellular Signaling Proteinscystatin F, mouseCystatinsHomeodomain ProteinsPhospholipase Dphospholipase D2Proto-Oncogene ProteinsRhox5 protein, mouseRNA, MessengerSocs2 protein, mouseSuppressor of Cytokine Signaling ProteinsTranscription Factorsdifferential gene expressionlymphomaMetastasisphospholipase D

Identifiers

PMID27807066
PMCPMC5219917
OpenAlexW2540456517

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.